A Pre-targeting Strategy for MR Imaging of Functional Molecules Using Dendritic Gd-Based Contrast Agents

Caravan P (2006) Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 35:512–523 Kobayashi H, Brechbiel MW (2003) Dendrimer-based macromolecular MRI contrast agents: characteristics and application. Mol Imaging 2:1–10 Accardo A, Tesauro D, Roscigno P et al (2004) Physicochemical properties of mixed micellar aggregates containing CCK peptides and Gd complexes designed as tumor specific contrast agents in MRI. J Am Chem Soc 126:3097–3107 Mulder WJ, Strijkers GJ, van Tilborg GA, Griffioen AW, Nicolay K (2006) Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 19:142–164 Nicolle GM, Toth E, Schmitt-Willich H, Raduchel B, Merbach AE (2002) The impact of rigidity and water exchange on the relaxivity of a dendritic MRI contrast agent. Chemistry 8:1040–1048 Toth EE, Vauthey S, Pubanz D, Merbach AE (1996) Water exchange and rotational dynamics of the dimeric gadolinium(III) complex [BO{Gd(DO3A)(H(2)O)}(2)]: a variable-temperature and -pressure (17)O NMR study(1). Inorg Chem 35:3375–3379 Toth E, Merbach AE (1998) Water exchange dynamics: the key for high relaxivity contrast agents in medical magnetic resonance imaging. ACH - Models Chem 135:873–884 Sipkins DA, Cheresh DA, Kazemi MR et al (1998) Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 4:623–626 Lee JH, Huh YM, Jun YW et al (2007) Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 13:95–99 Boswell CA, Eck PK, Regino CA et al (2008) Synthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimers. Mol Pharm 5:527–539 Kobayashi H, Sato N, Saga T et al (2000) Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity. Eur J Nucl Med 27:1334–1339 Green NM (1990) Avidin and streptavidin. Meth Enzymol 184:51–67 Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH (2003) Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 44:400–411 Sano K, Temma T, Kuge Y et al (2010) Radioimmunodetection of MT1-MMP relevant to tumor malignancy with pre-targeting method. Biol Pharm Bull 32:1589–1595 Axworthy DB, Reno JM, Hylarides MD et al (2000) Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 97:1802–1807 Paganelli G, Malcovati M, Fazio F (1991) Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system. International Workshop on Techniques for Amplification of Tumour Targetting. Nucl Med Commun 12:211–234 Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF (2006) Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 24:823–834 Sharkey RM, Karacay H, Cardillo TM et al (2005) Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 11:7109s–7121s Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25:9–34 Shiomi T, Okada Y (2003) MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 22:145–152 Laus S, Sour A, Ruloff R, Toth E, Merbach AE (2005) Rotational dynamics account for pH-dependent relaxivities of PAMAM dendrimeric, Gd-based potential MRI contrast agents. Chemistry 11:3064–3076 Foulon CF, Alston KL, Zalutsky MR (1997) Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and ((5-iodo-3-pyridinyl)carbonyl)norbiotinamide: two radioiodinated biotin conjugates with improved stability. Bioconjug Chem 8:179–186 Kudo T, Ueda M, Kuge Y et al (2009) Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells. J Nucl Med 50:942–949 Zhang Y, Wang C, Zhang Y, Sun M (2004) C6 glioma cells retrovirally engineered to express IL-18 and Fas exert FasL-dependent cytotoxicity against glioma formation. Biochem Biophys Res Commun 325:1240–1245 Temma T, Sano K, Kuge Y et al (2009) Achievement of MT1-MMP imaging shortly after radioligand administration by pretargeting strategy with SPECT. J Nucl Med 50(suppl):337P Kraeber-Bodere F, Rousseau C, Bodet-Milin C et al (2006) Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med 47:247–255 Zhu W, Okollie B, Bhujwalla ZM, Artemov D (2008) PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson Med 59:679–685 Iyer AK, Khaled G, Fang J, Maeda H (2006) Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11:812–818 Pantelias A, Pagel JM, Hedin N et al (2007) Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas. Blood 109:4980–4987 Sharkey RM, Karacay H, Griffiths GL et al (1997) Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconjug Chem 8:595–604 Lin Y, Pagel JM, Axworthy D et al (2006) A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res 66:3884–3892 Tomalia DA, Reyna LA, Svenson S (2007) Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans 35:61–67 Tomalia DA, Naylor AM, Goddard WA (1990) Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem Int Ed Engl 29:138–175 Kobayashi H, Sato N, Hiraga A et al (2001) 3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties. Magn Reson Med 45:454–460 Sato N, Kobayashi H, Hiraga A et al (2001) Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores. Magn Reson Med 46:1169–1173 Choyke PL, Kobayashi H (2006) Functional magnetic resonance imaging of the kidney using macromolecular contrast agents. Abdom Imaging 31:224–231 Kobayashi H, Brechbiel MW (2005) Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev 57:2271–2286 Roberts JC, Bhalgat MK, Zera RT (1996) Preliminary biological evaluation of polyamidoamine (PAMAM) starburst dendrimers. J Biomed Mater Res 30:53–65 Malik N, Wiwattanapatapee R, Klopsch R et al (2000) Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 65:133–148 Jevprasesphant R, Penny J, Jalal R et al (2003) The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 252:263–266 Buhaescu I, Izzedine H (2008) Gadolinium-induced nephrotoxicity. Int J Clin Pract 62:1113–1118 Kobayashi H, Kawamoto S, Jo SK et al (2003) Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem 14:388–394